A CpG oligodeoxynucleotide inducing anti-coxsackie B3 virus activity in human peripheral blood mononuclear cells

被引:13
作者
Cong, Zhongyi
Wan, Min
Wu, Xiuli
Wang, Li
Hu, Xiaoping
Yang, Fenglei
Bao, Musheng
Zhang, Xuesong
Chen, Jianzhu
Wang, Liying
Yu, Yongli
机构
[1] Jilin Univ, Coll Basic Med, Dept Immunol, Changchun, Peoples R China
[2] Jilin Univ, Coll Basic Med, Dept Biol Mol, Changchun, Peoples R China
[3] Blood Ctr Jilin Prov, Changchun, Peoples R China
[4] MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA
来源
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY | 2007年 / 51卷 / 01期
关键词
CpG ODN; coxsackie virus; IFN-alpha; IFN-beta; IFN-omega; IFN-gamma;
D O I
10.1111/j.1574-695X.2007.00266.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Coxsackie B3 virus (CVB3) is the most significant pathogen causing myocarditis in humans, and antiviral therapy would be most effective in the early stages of the disease. Here we provide evidence that BW001, a C-type CpG oligodeoxynucleotide, induces anti-CVB3 activity in human peripheral blood mononuclear cells (PBMCs). In parallel, we have demonstrated that BW001 induces human PBMCs to express mRNAs of multiple types of interferon (IFN), including IFN-alpha, IFN-beta, IFN-omega and IFN-gamma, and to express mRNAs of at least 11 subtypes of IFN-alpha. The induced IFNs may contribute to the anti-CVB3 activity. The results suggest that BW001 could be developed into a medication with the potential to treat CVB3 infectious diseases by inducing natural mixed IFNs.
引用
收藏
页码:26 / 34
页数:9
相关论文
共 52 条
[1]
[Anonymous], 2001, Anal Biochem
[2]
Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2 [J].
Ashkar, AA ;
Bauer, S ;
Mitchell, WJ ;
Vieira, J ;
Rosenthal, KL .
JOURNAL OF VIROLOGY, 2003, 77 (16) :8948-8956
[3]
Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis [J].
Banwell, B ;
Reder, AT ;
Krupp, L ;
Tenembaum, S ;
Eraksoy, M ;
Alexey, B ;
Pohl, D ;
Freedman, M ;
Schelensky, L ;
Antonijevic, I .
NEUROLOGY, 2006, 66 (04) :472-476
[4]
Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide [J].
Bao, MS ;
Zhang, Y ;
Wan, M ;
Dai, L ;
Hu, XP ;
Wu, XL ;
Wang, L ;
Deng, P ;
Wang, JZ ;
Chen, JZ ;
Liu, YJ ;
Yu, YL ;
Wang, LY .
CLINICAL IMMUNOLOGY, 2006, 118 (2-3) :180-187
[5]
Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon α genes [J].
Barnes, BJ ;
Moore, PA ;
Pitha, PM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (26) :23382-23390
[6]
A comparative amplification of five different genomic regions on Coxsackie A and B viruses. Implications in clinical diagnostics [J].
Bolanaki, E ;
Kottaridi, C ;
Markoulatos, P ;
Margaritis, L ;
Katsorchis, T .
MOLECULAR AND CELLULAR PROBES, 2005, 19 (02) :127-135
[7]
Intravenous immune globulin in the therapy of peripartum cardiomyopathy [J].
Bozkurt, B ;
Villaneuva, FS ;
Holubkov, R ;
Tokarczyk, T ;
Alvarez, RJ ;
MacGowan, GA ;
Murali, S ;
Rosenblum, WD ;
Feldman, AM ;
McNamara, DM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (01) :177-180
[8]
Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-α [J].
Braiteh, F ;
Boxrud, C ;
Esmaeli, B ;
Kurzrock, R .
BLOOD, 2005, 106 (09) :2992-2994
[9]
Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity [J].
Cajean-Feroldi, C ;
Nosal, F ;
Nardeux, PC ;
Gallet, X ;
Guymarho, J ;
Baychelier, F ;
Sempé, P ;
Tovey, MG ;
Escary, JL ;
Eid, P .
BIOCHEMISTRY, 2004, 43 (39) :12498-12512
[10]
In vitro inhibition of SARS virus replication by human Interferons [J].
Dahl, H ;
Linde, A ;
Strannegård, Ö .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2004, 36 (11-12) :829-831